What Остеохин Treats: Main Uses and Benefits

Остеохин is commonly used to help with managing symptoms related to physical discomfort associated with osteoarthritis (OA). This is a condition characterized by periods of heightened symptoms. The product is applied across therapeutic domains where additional symptomatic support is needed.

The product may assist with easing symptom clusters that interfere with daily functioning, such as joint pain, joint stiffness, and reduced mobility in areas like the knees, hips, and hands. It contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.

The use of this supportive assistance is often relevant when short-term symptomatic management is appropriate for conditions involving episodic or fluctuating manifestations. It helps improve day-to-day comfort during symptomatic periods and supports patients during episodes of heightened discomfort. This support is commonly used to help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for symptoms related to physical discomfort

Regulatory References

1. NIH NCCIH overview of Glucosamine and Chondroitin

Who Can and Cannot Use Остеохин?

The population eligibility for Остеохин (Ipriflavone) is defined by regulatory criteria detailed in official prescribing information.

---

Official Eligibility Scope

Classification	Population Status
Use Allowed (Established)	Adults, especially postmenopausal women.
Use Contraindicated	Patients with known hypersensitivity to Ipriflavone or its excipients.
Use Not Recommended	Pediatric patients (under 18 years), pregnant women, and breastfeeding women.

---

Specific Population Restrictions

Age-Related Rules: Use is established only in the adult population; safety and efficacy are not established for those below 18 years of age.

Organ Function: Caution and close monitoring are required for patients with renal failure. Use is generally not recommended in cases of severe hepatic impairment due to the drug's metabolism.

Conditional Use: The medicine should be used with special caution or restriction in patients with a weak immune system or pre-existing lymphocytopenia, as Ipriflavone has been documented to potentially affect white blood cell counts. Regulatory documents explicitly advise avoiding use during both pregnancy and lactation due to a lack of sufficient safety data.

Interaction Map: Interactions with other medicines and products — official regulatory information for Остеохин

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	CYP1A2 Substrates; CYP2C9 Substrates; Estrogen; Immunosuppressants; Calcium Supplements
Specific interacting medicines (if explicitly listed)	Theophylline; Warfarin; Phenytoin; Caffeine
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic: Inhibition of hepatic enzymes (CYP1A2 and CYP2C9); Pharmacodynamic: Potentiation of skeletal effects; Additive risk of toxicity
Timing-based interaction rules (if applicable)	Some sources recommend separating the administration time from Calcium supplements to avoid potential absorption interference.
Interaction-related restrictions	Co-administration with Immunosuppressants is advised to be avoided or used only under physician supervision due to the compounded risk of lymphocytopenia.

---

Interaction Classifications (High-Level)

Category	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Use-with-caution combinations (CYP substrates); Combination with Restriction (Immunosuppressants)
Regulatory basis (EMA / FDA / etc.)	Information is derived from government-aligned prescribing information (e.g., SmPC, FDA Prescribing Information, and public health monographs).

---

Resulting Interaction Structure

Official interaction statements:

• Ipriflavone is documented as an inhibitor of the hepatic enzymes CYP1A2 and CYP2C9, a pharmacokinetic mechanism altering the clearance of co-administered medicines.
• Co-administration with Theophylline results in increased systemic exposure due to reduced clearance via CYP1A2 inhibition.
• Ipriflavone may increase the plasma concentrations of CYP2C9 substrates, including specific drugs like Warfarin and Phenytoin.
• Co-administration with Estrogen is noted to potentiate the anti-osteoporosis benefits while also potentially increasing the risk of Estrogen's effects on the uterus.
• Administration of Ipriflavone and Calcium supplements may require separation in time to prevent absorption interference.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the product's interaction structure primarily through the pharmacokinetic inhibition of specific hepatic enzymes (CYP1A2 and CYP2C9) leading to increased drug exposure of substrates. The official profile also includes explicit restrictions against combining the drug with Immunosuppressants due to an additive risk of toxicity, a key regulatory constraint.

The mechanism of action for Остеохин is based on a dual-component pharmacodynamic strategy that influences both bone tissue removal and the systemic availability of minerals required for biomineralization.

Anti-Resorptive Action

The Etidronic Acid component, a bisphosphonate, acts on the bone remodeling pathway by selectively binding to the hydroxylapatite mineral matrix. It is subsequently internalized by osteoclasts during bone resorption. The drug disrupts essential cellular energy processes within these cells, resulting in the functional impairment and suppression of osteoclast activity. This mechanistic cascade leads directly to a reduced rate of bone breakdown and the retention of bone tissue.

Mineral Homeostasis Modulation

The Dihydroxycholecalciferol ( Calcitriol) component modulates calcium and phosphate homeostasis. It functions as an agonist of the Vitamin D Receptor (VDR), initiating gene transcription that enhances the synthesis of calcium-binding proteins. This results in a substantial increase in the intestinal absorption of dietary calcium and phosphate.

Physiological Consequence

This coupling of retarded bone matrix degradation and increased mineral availability modulates the bone remodeling cycle towards a net reduction in resorption relative to formation, leading to the physiological consequence of an increase in bone mineral content.

The use of Остеохин follows a defined administration pattern. The medication's active ingredient, Ipriflavone, is administered via the oral route as an oral solid preparation.

Standardized Administration

The standard total daily dose is 600 mg. This amount is typically administered in divided doses throughout the day, typically consisting of 200 mg three times daily (t.i.d.). This specific frequency pattern is utilized to maintain consistent systemic levels of the compound over 24 hours. A core instruction for use is the requirement for the medication to be taken with food. This administration timing is intended to optimize the drug's absorption and ensure bioavailability. Furthermore, administration guidelines often include a supportive daily intake of elemental calcium, typically around 1,000 mg.

Duration and Adjustments

The regimen is defined by a long-term, continuous administration pattern. The use of Ipriflavone is not typically cyclic and is maintained over a prolonged duration, sometimes for periods exceeding two years, due to the cumulative nature of its action on bone turnover. For specific patient populations, a dosage adjustment is applied: a reduction in the total daily dose (e.g., to 200 mg or 400 mg) is involved for individuals with confirmed severe renal impairment. The standard adult dose, however, generally applies to older patients without explicit age-related modification.

Research evidence / Overview of studies for Остеохин

Studies Examining Bone Mineral Density (BMD) Outcomes

The core research for Остеохин (Ipriflavone) was studied for its application in contexts related to bone structure and mineralization, particularly in individuals facing a risk of mineral loss. The evidence base includes multiple large, Randomized Controlled Trials (RCTs) and comprehensive research syntheses, such as meta-analyses. These trials evaluated the medicine, often against a placebo, in cohorts where mandatory calcium supplementation was also used.

Researchers primarily measured changes in Bone Mineral Density (BMD) at critical sites, like the spine and hip. Studies also monitored the drug's effect on certain biochemical markers of bone turnover as part of studies evaluating bone-related processes. The primary populations evaluated were postmenopausal women with low bone mass or osteoporosis.

Studies Examining Symptomatic and Physical Function Outcomes

Data on symptomatic endpoints were collected in studies conducted during periods of increased symptom activity where the medicine was evaluated in patients with skeletal conditions. This research was concerned with outcomes related to physical discomfort, outcomes reflecting daily functioning, and patient-reported outcomes describing perceived discomfort.

These symptomatic endpoints, such as changes in bone pain and mobility, were mainly collected as secondary or exploratory outcomes within the larger BMD trials. Evidence remains limited for these specific symptomatic outcomes, and the reported data are characterized by heterogeneity (variability) and a lack of dedicated trials.

---

What Research Gaps and Uncertainties Exist

The overall research landscape includes several areas where certainty remains low. The evidence provides limited information to fully characterize the findings related to long-term fracture incidence, as most trials were not statistically powered for this purpose. Furthermore, a limitation is that findings related to BMD sometimes were mixed across large trials, which contributed to conflicting conclusions in the scientific literature. Comparative evidence is lacking for many aspects of the drug's use, and inconsistencies in the results mean evidence quality varies across studies.

Common questions about Остеохин (FAQ)

---

Q: Can I take Остеохин if I have mild kidney problems?

A: Official information indicates that a specific dosage reduction is mandated for individuals with severe renal (kidney) impairment. For less severe kidney issues, regulatory guidance advises that caution and close monitoring are typically recommended. Any necessary adjustments to treatment due to kidney function must be determined by a healthcare provider.

---

Q: What is the exact chemical structure of Ipriflavone?

A: Ipriflavone is defined in official regulatory and chemical databases as a synthetic isoflavone derivative. Its chemical structure is formally known as 3-phenyl-7-propan-2-yloxychromen-4-one, and its chemical formula is C18H16O3.

---

Q: How long after taking a calcium supplement can I take Остеохин?

A: Regulatory guidance suggests that separating the administration time of this medication from calcium supplements may be necessary. This precaution is intended to avoid potential interference that could reduce the absorption of the medicine. A specific time interval for separation is not consistently specified in the standard regulatory text.

---

Q: Does Остеохин come in a liquid form?

A: According to the official product information, this medicine is specified as an Oral Solid Preparation, such as a tablet. The standard regulatory documents do not confirm the availability of other forms, such as a liquid.

---

Q: What should I do if I miss a dose of Остеохин?

A: Instructions on managing a missed dose are typically contained within the Dosage and Administration section of official prescribing information. These instructions are intended to help maintain the required consistency of treatment. Patients are advised to refer to the official prescribing information or consult a healthcare provider for specific directions if a dose is missed.

How to Store and Dispose of Остеохин?

The storage and disposal of this medication are subject to official regulatory requirements designed to maintain product integrity and ensure patient safety.

Storage & Disposal Scope	Official Regulatory Requirement
Labeled Storage Temperature Requirements:	Store the tablets at room temperature, avoiding excessive heat.
Light/Moisture Protection Requirements:	Protect the medication from excessive moisture and humidity.
Child-Protection Storage Requirements:	Must be stored out of the sight and reach of children.
Packaging-Related Storage Rules:	Keep the oral tablets in their original container until use.
Disposal Instructions:	Dispose of unused or expired product according to local official regulations.
Environmental Disposal Requirements:	Do not dispose of the medicine by flushing it down a sink or toilet (wastewater).

Official regulatory documents define the storage environment by mandating that the oral tablets be protected from excessive heat and moisture to maintain product stability. This requires the medicine to be kept in its original packaging and not used past the expiration date. Furthermore, the official label universally requires that the medication be stored out of the reach of children and mandates specific disposal rules, requiring that the product be discarded only in accordance with local regulations.